DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Dyslipidemia | Landscape & Forecast | Disease Landscape & Forecast

Dyslipidemia | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL)-cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL)-cholesterol, and other novel biomarkers is ongoing, with the aim of ultimately providing CV benefits. During the 2017-2027 forecast period, the dyslipidemia market is expected to have two distinct phases: 1) early contraction owing largely to the genericization of the dominant statin class, and 2) marked growth due to the emergence of novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, Amarin’s Vascepa, Kowa Pharmaceuticals’ Parmodia (pemafibrate), The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, and AstraZeneca’s Epanova.

Questions Answered:

  • What impact will the genericization of AstraZeneca’s Crestor (rosuvastatin)and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) have on the dyslipidemia market?
  • How will CV outcomes data for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and omega-3 fatty acid compounds affect the market?
  • How will the anticipated launch of Esperion Therapeutics’ orally administered bempedoic acid affect the use of the injectable PCSK9 inhibitors? Which products will achieve the greatest use and why?
  • What impact will the anticipated launch of Kowa’s Parmodia and AstraZeneca’s Epanova have on the management of hypertriglyceridemia?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • November 2018
      • September 2018
      • August 2018
      • June 2018
      • October 2017
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Dyslipidemia?
        • What Factors Are Constraining the Market for Dyslipidemia?
      • Drug-Class-Specific Trends
        • Statins
        • Cholesterol Absorption Inhibitors
        • PCSK9 Inhibitors
        • ACL Inhibitors
        • PPAR Modulators
        • Omega-3 Fatty Acid Compounds
        • BET Inhibitors
        • Bile Acid Sequestrants (Resins)
        • Niacin Derivatives
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Primary and Secondary Prevention Dyslipidemia
        • Diagnosed Prevalent Cases of Dyslipidemia
        • Drug-Treated Cases of Dyslipidemia
    • Current Treatment
      • Key Findings
        • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Statins
        • Cholesterol Absorption Inhibitors
        • Bile Acid Sequestrants
        • PCSK9 Inhibitors
        • PPAR Modulators
        • Omega-3 Fatty Acid Compounds
        • Niacin Derivatives
        • Treatments for Rare Lipid Disorders
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Country-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Dyslipidemia
    • Emerging Therapies
      • Key Findings
        • Expert Insight
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Dyslipidemia
        • PCSK9 Inhibitors
        • Omega-3 Fatty Acid Compounds
        • CETP Inhibitors
        • ACL Inhibitors
        • BET Inhibitors
        • Apolipoprotein-CIII Antagonists
        • Fixed-Dose Combinations
        • Angiopoietin-like Protein 3 (ANGPTL3) Inhibitor
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Dyslipidemia
      • Key Discontinuations and Failures in Dyslipidemia
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Dyslipidemia Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Surbhi Gupta, Masters in Pharmacy; Ema Rodrigues, DSc, MPH
  • Surbhi Gupta is an Insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group and has worked on contents on pulmonary hypertension and obesity. She completed her Masters with specialization in Pharmacology, and a Bachelor's degree in Pharmacy from the University Of Delhi. Before joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve, where she was involved in competitive intelligence projects across multiple indications (such as atrial fibrillation, ACS, VTE, renal anemia, and several oncology indications). She also worked as a Medical writer at the clinical research organization, Apcer Pharma.

  • Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degree (MPH, ) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.              

Purchase Report

Recent reports:
You may also be interested in: